According to a recent study from Stanford University, a newly identified peptide known as BRP may offer a safer alternative to Ozempic for weight loss. Unlike GLP-1 receptor agonists such as Ozempic, BRP works independently of the incretin pathway and does not cause nausea or aversion in preclinical trials. Researchers found that BRP reduces food intake by up to 50% in animal models, promotes fat burning, and enhances energy expenditure.
BRP functions through hypothalamic activation and improved lipid oxidation, suggesting a dual-action approach to weight loss. While Ozempic has demonstrated notable efficacy in clinical trials, it is often associated with gastrointestinal side effects and muscle mass loss. In contrast, BRP’s unique mechanism may allow for improved tolerability and adherence, though further human trials are necessary to confirm its effectiveness.
BRP could become a promising natural alternative for sustainable weight management if proven safe in clinical studies.
Source: Coassolo, L., B. Danneskiold-Samsøe, N., Nguyen, Q. et al. (2025). Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide. Nature. https://doi.org/10.1038/s41586-025-08683-y
